Drug Trial Radar · NCT06837155
A QT/QTc Evaluation Study of TS-172 in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Mar 3, 2025
Primary completion
May 20, 2025
Study completion May 26, 2025
Sponsor
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 39 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A clinical study to evaluate the effects on QT/QTc interval of TS-172 in healthy adults subjects
Conditions
- Healthy Volunteers
Interventions
TS-172 20 mgDrug
oral administration of TS-172 20 mg
TS-172 90 mgDrug
oral administration of TS-172 90 mg
MoxifloxacinDrug
oral administration of moxifloxacin 400 mg
PlaceboDrug
oral administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- QTcF:QT-interval corrected by Fridericia corrections in Holter ECGsTime frame: Up to 24 hours postdose during each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.